This receptor is known to play a key role in various cancers, including non-small-cell lung, breast, and colorectal cancer, which led to the approval of both small-molecule tyrosine kinase inhibitors and antibodies targeting EGFR [18]. The gene discussed is EGFR; the disease is cancer.